Novel PPARγ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis

Inflammatory Bowel Diseases

Volumn 22, Issue 2, 2016, Pages 279-292

  Speca, Silvia ^a,b,c   Rousseaux, Christel ^d   Dubuquoy, Caroline ^d   Rieder, Florian ^e   Vetuschi, Antonella ^c   Sferra, Roberta ^c   Giusti, Ilaria ^c   Bertin, Benjamin ^a,f   Dubuquoy, Laurent ^a,f   Gaudio, Eugenio ^g   Desreumaux, Pierre ^a,b,f   Latella, Giovanni ^c  

^a UNIVERSITÉ DE LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d IBD   (France)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIV LILLE   (France)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

inflammatory bowel disease; intestinal fibrosis; new antifibrotic therapeutic strategies; peroxisome proliferator activated receptor; TGF signal transduction pathway

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ALPHA ACTIN; ALPHA ACTIN 1; ALPHA ACTININ 1; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKERATIN 20; FIBRONECTIN; FIBRONECTIN 1; GED 0507 34LEVO; GLYCOPROTEIN; GLYCOPROTEIN A33; INTERLEUKIN 13; MESALAZINE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 3-(4-AMINOPHENYL)-2-METHOXYPROPIONIC ACID; ANILINE DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL STIMULATION; CHRONIC DISEASE; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL COLITIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINAL FIBROSIS; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; INTESTINE ULCER; MOUSE; MYOFIBROBLAST; NONHUMAN; ORGAN WEIGHT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; COLITIS; COMPLICATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; FIBROBLAST; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; INFLAMMATION; INTESTINE; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; COLITIS; FIBROBLASTS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INTESTINES; MICE; MICE, INBRED C57BL; PHENYLPROPIONATES; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84955598863     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000618     Document Type: Article

References (51)

1. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028-1040.
2. Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2011;300:677-683.
3. Rieder F, Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228-235.
4. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448.
5. Rieder F, Zimmermann EM, Remzi FH, et al. Crohn's disease complicated by strictures: a systematic review. Gut. 2013;62:1072-1084.
6. Rieder F, Karrasch T, Ben-Horin S, et al. Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing. J Crohns Colitis. 2012;6:373-385.
7. Speca S, Giusti I, Rieder F, et al. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol. 2012;18:3635-3661.
8. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002;118:211-215.
9. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta/smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 2001;276:17058-17062.
10. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor a/smad signal in hepatic fibrogenesis. Gut. 2007;56:284-292.
11. Bonniaud P, Margetts PJ, Ask K, et al. TGF-b and smad3 signaling link inflammation to chronic fibrogenesis. J Immunol. 2005;175:5390-5395.
12. Gauldie J, Bonniaud P, Sime P, et al. TGF-beta, smad3 and the process of progressive fibrosis. Biochem Soc Trans. 2007;35:661-664.
13. Latella G, Rogler G, Bamias G, et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. 2014;8:1147-1165.
14. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58:777-789.
15. Rieder F, Kessler S, Sans M, et al. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol. 2012;303:G786-G801.
16. Vallance BA, Gunawan MI, Hewlett B, et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol. 2005;289:G116-G128.
17. Latella G, Vetuschi A, Sferra R, et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur J Clin Invest. 2009;39:145-156.
18. Wei J, Ghosh AK, Sargent JL, et al. PPARg downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5: e13778.
19. Ghosh AK, Bhattacharyya S, Wei J, et al. Peroxisome proliferator-activated receptor-gamma abrogates smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J. 2009;23: 2968-2977.
20. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55:1341-1349.
21. Yang L, Stimpson SA, Chen L, et al. Effectiveness of the PPARg agonist, GW570, in liver fibrosis. Inflamm Res. 2010;59:1061-1071.
22. Rieder F, Georgieva M, Schirbel A, et al. Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis. 2010;16: 1505-1513.
23. Latella G, Sferra R, Speca S, et al. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. 2013;17: 1283-1304.
24. Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest. 2009;89:47-58.
25. Aoki Y, Maeno T, Aoyagi K, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration. 2009;77:311-319.
26. Speca S, Dubuquoy L, Desreumaux P. Peroxisome proliferator-activated receptor gamma in the colon: inflammation and innate antimicrobial immunity. J Clin Gastroenterol. 2014;48:23-27.
27. Bertin B, Dubuquoy L, Colombel JF, et al. PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013;14: 1501-1507.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
29. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastroinest Liver Physiol. 2000;279:G653-G659.
30. Lee J, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172:973-981.
31. Flier SN, Tanjore H, Kokkotou EG, et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibro-sis. J Biol Chem. 2010;285:20202-20212.
32. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. 2011;179:2660-2673.
33. Pirat C, Farce A, Lebègue N, et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J Med Chem. 2012;55:4027-4061.
34. Desreumaux P. Understanding the mechanism of 5-ASA in treating colonic inflammation. Gastroenterol Hepatol. 2008;4:319-320.
35. Zhao C, Chen W, Yang L, et al. PPARgamma agonists prevent TGFbeta1/smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun. 2006;350:385-391.
36. Zhang GY, Cheng T, Zheng MH, et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. Arch Dermatol Res. 2009; 301:515-522.
37. Galli A, Crabb D, Price D, et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hep-atology. 2000;31:101-108.
38. Xu HE, Lambert MH, Montana VG, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Atl Acad Sci USA. 2001;98:13919-13924.
39. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122:1924-1940.
40. Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 2000;119:466-478.
41. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem. 2000;275: 35715-35722.
42. Planaguma A, Claria J, Miquel R, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005;19:1120-1122.
43. Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dom-inated inflammatory response. J Clin Invest. 1999;104:777-785.
44. Chiaramonte MG, Cheever AW, Malley JD, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology. 2001;34:273-282.
45. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99-106.
46. Fichtner-Fiegl S, Strober W, Geissler EK, et al. Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol. 2008;1:S24-S27.
47. Dammeier J, Brauchle M, Falk W, et al. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol. 1998;30:909-922.
48. di Mola FF, Di Sebastiano P, Gardini A, et al. Differential expression of connective tissue growth factor in inflammatory bowel disease. Digestion. 2004;69:245-253.
49. Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 2003;4:216.
50. Kossakowska AE, Edwards DR, Lee SS, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol. 1998;153:1895-1902.
51. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol. 2008; 24:462-468.